Plaque Psoriasis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Bio-Thera Solutions, Jiangsu HengRui Medicine, Arcutis

The Plaque Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Plaque Psoriasis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Plaque Psoriasis Market.

Some of the key takeaways from the Plaque Psoriasis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Plaque Psoriasis treatment therapies with a considerable amount of success over the years. 
• Plaque Psoriasis companies working in the treatment market are Azora Therapeutics, Artax Biopharma Inc., Hangzhou Highlightll Pharmaceutical, Bio-Thera Solutions, Jiangsu HengRui Medicine, Arcutis Biotherapeutics, Jiangsu Hengrui Medicine, Akeso Biopharma, Dong-A ST Co., Ltd., Suzhou Zelgen Biopharma, Sun Pharma, Nimbus Therapeutics, Meiji Pharma, Affibody, GC Cell Corporation, and others, are developing therapies for the Plaque Psoriasis treatment 

• Emerging Plaque Psoriasis therapies in the different phases of clinical trials are- AT193, AX-158, TLL018, BAT2306, SHR-1314, ARQ-151, SHR 1314, AK101, DMB-3115, Jaktinib, SCD-044, NDI 034858, ME3183, ABY-035, CT 303, and others are expected to have a significant impact on the Plaque Psoriasis market in the coming years.   
• In October 2022, Bio-Thera Solutions initiated a multicenter, randomized, double-blind, parallel-arm, Phase 3 study to compare efficacy and safety of BAT2306 with Cosentyx® in patients with moderate to severe plaque psoriasis. The study is composed of a ≤ 28-day screening period, a 24-week initial treatment period (Treatment Period 1[TP1]), and a 28-week secondary treatment period (Treatment Period 2 [TP2]).
• In May 2022, Deucravacitinib treatment for adult patients with moderate to severe plaque psoriasis has been shown to have lasting efficacy and a consistent safety profile, according to two-year data by the POETYK PSO long-term extension (LTE) experiment released by Bristol Myers Squibb. Clinical efficacy persisted for up to two years after starting deucravacitinib treatment, with response rates of 77.7% and 58.7% for static Physicians Global Assessment (sPGA) 0/1 (clean/almost clear skin) and psoriasis area and severity index (PASI) 75, respectively, at Week 60 in the LTE.
• In April 2022, Amgen released the preliminary findings of a Phase 3 research comparing ABP 654 to STELARA® (ustekinumab) in treating adult patients with moderate to severe plaque psoriasis. The primary efficacy endpoint of the research was achieved, showing no clinically significant differences between ABP 654 and STELARA.
• In March 2022, At the 2022 American Academy of Dermatology annual meeting, which was held in Boston, Massachusetts, Arcutis Biotherapeutics revealed fresh pooled findings from the DERMIS Phase III trials of roflumilast cream are available in four abstracts. Roflumilast is a very effective and selective PDE4 inhibitor that Arcutis is researching as a non-steroidal topical treatment for a variety of inflammatory skin conditions, including plaque psoriasis.
• In March 2022, Due to an unexpected delay in the gathering of trial data, Can-Fite BioPharma Ltd. said that top line data from its Phase III ComfortTM study of Piclidenoson in the treatment of moderate-to-severe plaque psoriasis are slated to be released in Q2 2022. Over 400 patients from 30 sites in Europe, Israel, and Canada participated in the trial.
• In May 2022, In both healthy volunteers and patients with moderate-to-severe psoriasis, Nimbus Therapeutics’ experimental oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, was studied in several Phase 1 clinical investigations.NDI-034858 is the subject of active psoriatic arthritis (NCT05153148) and moderate-to-severe plaque psoriasis (NCT04999839) phase 2b clinical investigations.

Plaque Psoriasis Overview

Psoriasis vulgaris, also known as plaque psoriasis, is a persistent (chronic) autoimmune condition that accelerates cell division. It is a kind of psoriasis that results in plaques on the skin, which are thick, scaly regions. Approximately 8 million Americans suffer from the skin condition psoriasis.

Get a Free Sample PDF Report to know more about Plaque Psoriasis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/plaque-psoriasis-pipeline-insight

Emerging Plaque Psoriasis Drugs Under Different Phases of Clinical Development Include:

• AT193: Azora Therapeutics
• AX-158: Artax Biopharma Inc.
• TLL018: Hangzhou Highlightll Pharmaceutical
• BAT2306: Bio-Thera Solutions
• SHR-1314: Jiangsu HengRui Medicine
• ARQ-151: Arcutis Biotherapeutics
• SHR 1314: Jiangsu Hengrui Medicine
• AK101: Akeso Biopharma
• DMB-3115: Dong-A ST Co., Ltd.
• Jaktinib: Suzhou Zelgen Biopharma
• SCD-044: Sun Pharma
• NDI 034858: Nimbus Therapeutics
• ME3183: Meiji Pharma
• ABY-035: Affibody
• CT 303: GC Cell Corporation

Plaque Psoriasis Route of Administration

Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Plaque Psoriasis Molecule Type

Plaque Psoriasis Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine 

Plaque Psoriasis Pipeline Therapeutics Assessment

• Plaque Psoriasis Assessment by Product Type
• Plaque Psoriasis By Stage and Product Type
• Plaque Psoriasis Assessment by Route of Administration
• Plaque Psoriasis By Stage and Route of Administration
• Plaque Psoriasis Assessment by Molecule Type
• Plaque Psoriasis by Stage and Molecule Type

DelveInsight’s Plaque Psoriasis Report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Plaque Psoriasis product details are provided in the report. Download the Plaque Psoriasis pipeline report to learn more about the emerging Plaque Psoriasis therapies

Some of the key companies in the Plaque Psoriasis Therapeutics Market include:

Key companies developing therapies for Plaque Psoriasis are – Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others.

Plaque Psoriasis Pipeline Analysis:

The Plaque Psoriasis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Plaque Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Plaque Psoriasis Treatment.
• Plaque Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Plaque Psoriasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Plaque Psoriasis drugs and therapies

Plaque Psoriasis Pipeline Market Drivers

• Growing worldwide prevalence, ongoing research and development activities to identify novel and targeted therapies, increase in Awareness about the disease are some of the important factors that are fueling the Plaque Psoriasis Market.

Plaque Psoriasis Pipeline Market Barriers

• However, poor adherence and compliance with medications, challenging disease in terms of management and other factors are creating obstacles in the Plaque Psoriasis Market growth.

Scope of Plaque Psoriasis Pipeline Drug Insight    

• Coverage: Global
• Key Plaque Psoriasis Companies: Azora Therapeutics, Artax Biopharma Inc., Hangzhou Highlightll Pharmaceutical, Bio-Thera Solutions, Jiangsu HengRui Medicine, Arcutis Biotherapeutics, Jiangsu Hengrui Medicine, Akeso Biopharma, Dong-A ST Co., Ltd., Suzhou Zelgen Biopharma, Sun Pharma, Nimbus Therapeutics, Meiji Pharma, Affibody, GC Cell Corporation, and others
• Key Plaque Psoriasis Therapies: AT193, AX-158, TLL018, BAT2306, SHR-1314, ARQ-151, SHR 1314, AK101, DMB-3115, Jaktinib, SCD-044, NDI 034858, ME3183, ABY-035, CT 303, and others
• Plaque Psoriasis Therapeutic Assessment: Plaque Psoriasis current marketed and Plaque Psoriasis emerging therapies
• Plaque Psoriasis Market Dynamics: Plaque Psoriasis market drivers and Plaque Psoriasis market barriers 

Request for Sample PDF Report for Plaque Psoriasis Pipeline Assessment and clinical trials

Table of Contents 

1. Plaque Psoriasis Report Introduction

2. Plaque Psoriasis Executive Summary

3. Plaque Psoriasis Overview

4. Plaque Psoriasis- Analytical Perspective In-depth Commercial Assessment

5. Plaque Psoriasis Pipeline Therapeutics

6. Plaque Psoriasis Late Stage Products (Phase II/III)

7. Plaque Psoriasis Mid Stage Products (Phase II)

8. Plaque Psoriasis Early Stage Products (Phase I)

9. Plaque Psoriasis Preclinical Stage Products

10. Plaque Psoriasis Therapeutics Assessment

11. Plaque Psoriasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Plaque Psoriasis Key Companies

14. Plaque Psoriasis Key Products

15. Plaque Psoriasis Unmet Needs

16 . Plaque Psoriasis Market Drivers and Barriers

17. Plaque Psoriasis Future Perspectives and Conclusion

18. Plaque Psoriasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services